MYGN Q2 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q2 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$212M+15.3% YoY

Gross Profit

$147M69.6% margin

Operating Income

-$37M-17.3% margin

Net Income

-$37M-17.4% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$6M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$345M

Stockholders' Equity

$741M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$212M	$184M	+15.3%
Gross Profit	$147M	$126M	+17.0%
Operating Income	-$37M	-$114M	+67.9%
Net Income	-$37M	-$116M	+68.4%

Geographic Segments

UNITED STATES

$195M92%

Non-US

$17M8%